Note: The full article and accompanying features are only available whilst being signed in.
Summary
Adherence to prescribed medication, particularly for long-term conditions, poses a tremendous challenge to the world's Pharmaceutical companies. Seventy percent of patients who begin a Pharmaceutical therapy discontinue it within one year. The greatest drop in patient compliance occurs after the first 6 months of treatment. This represents a significant loss for Pharmaceutical companies who have spent millions to get those initial prescriptions.
To address this, many different patient compliance / adherence programs are implemented. However, these are doomed to fail unless organizations also evaluate underlying causes for non-compliance with their brand as well as the bottom line return on investment for specific compliance activities, and take these into account when designing and implementing patient compliance programs.
Only by doing this can Brand Managers increase market share and revenues from patient compliance for their brands while significantly improving clinical outcomes for patients.
Want more?
The content of this page been summarized. To view the full content, please register or sign in to the Eularis web site.
Register with Eularis
or
Sign in